

Attorney Docket No. 08702.0090-04000  
Application No. 09/878,574

**CLAIM LISTING**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-39. (Canceled)

40. (Previously presented) A method for treating a subject having an inflammatory disorder, wherein the inflammatory disorder is characterized by excessive GM4,6D activity or excessive GM4,6D nucleic acid expression, comprising administering a therapeutically effective amount of an antibody capable of binding to a polypeptide comprising the amino acid sequence of either SEQ ID NO:2 or SEQ ID NO: 3.
41. (Previously presented) The method of claim 40, wherein the antibody is a monoclonal antibody.
42. (Previously presented) The method of claim 40, wherein the antibody is a polyclonal antibody.
43. (Previously presented) The method of claim 40, wherein the antibody is capable of binding to a polypeptide comprising the amino acid sequence of SEQ ID NO: 3.
44. (Previously presented) A method for treating a subject having an inflammatory disorder characterized by excessive GM4,6D activity or excessive GM4,6D nucleic acid expression and chosen from arthritis, transplant rejection, asthma, sepsis, reperfusion injury, stroke and infection, comprising administering a therapeutically effective amount of an antibody capable of binding to a polypeptide comprising the amino acid sequence of either SEQ ID NO:2 or SEQ ID NO: 3.
45. (Previously presented) The method of claim 44, wherein the antibody is a monoclonal antibody.

Attorney Docket No. 08702.0090-04000  
Application No. 09/878,574

46. (Previously presented) The method of claim 44, wherein the antibody is a polyclonal antibody.

47. (Previously presented) The method of claim 44, wherein the inflammatory disorder is arthritis.

48. (Previously presented) The method of claim 44, wherein the inflammatory disorder is transplant rejection.

49. (Previously presented) The method of claim 44, wherein the inflammatory disorder is asthma.

50. (Previously presented) The method of claim 44, wherein the inflammatory disorder is stroke.

51. (Previously presented) The method of claim 44, wherein the inflammatory disorder is infection.

52. (Previously presented) A method of treating a subject having an inflammatory disorder characterized by excessive GM4,6D polypeptide activity comprising administering to the subject a compound, wherein said compound modulates GM4,6D polypeptide activity when combined with a substrate and a GM4,6D polypeptide chosen from:

(1) a polypeptide encoded by the nucleotide sequence of SEQ ID NO: 1;

(2) a polypeptide of SEQ ID NO: 2;

(3) a polypeptide of SEQ ID NO: 3;

(4) and a fragment of the polypeptide of SEQ ID NO:2 or SEQ ID NO: 3, which has GM4,6D activity.

Attorney Docket No. 08702.0090-04000  
Application No. 09/878,574

53. (Previously presented) The method of claim 52, wherein the compound is an antibody that binds the GM4,6D polypeptide.
54. (Previously presented) The method of claim 52, wherein the antibody is a monoclonal antibody.
55. (Previously presented) The method of claim 52, wherein the antibody is a polyclonal antibody.
56. (New) The method of claim 40, wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
57. (New) The method of claim 40, wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.
58. (New) The method of claim 40, wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:3.
59. (New) The method of claim 44, wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
60. (New) The method of claim 44, wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:3.
61. (New) The method of claim 44, wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.
62. (New) The method of claim 44, wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:3.
63. (New) The method of claim 44, wherein the inflammatory disorder is sepsis.

Attorney Docket No. 08702.0090-04000  
Application No. 09/878,574

- 64. (New) The method of claim 44, wherein the inflammatory disorder is reperfusion injury.
- 65. (New) The method of claim 53, wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
- 66. (New) The method of claim 53, wherein the antibody is capable of binding a polypeptide comprising the amino acid sequence of SEQ ID NO:3.
- 67. (New) The method of claim 53, wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:2.
- 68. (New) The method of claim 53, wherein the antibody is capable of binding a polypeptide consisting of the amino acid sequence of SEQ ID NO:3.
- 69. (New) The method of claim 52, wherein the inflammatory disorder is chosen from arthritis, transplant rejection, asthma, sepsis, reperfusion injury, stroke and infection.
- 70. (New) The method of 69, wherein the inflammatory disorder is arthritis.
- 71. (New) The method of claim 69, wherein the inflammatory disorder is transplant rejection.
- 72. (New) The method of claim 69, wherein the inflammatory disorder is asthma.
- 73. (New) The method of claim 69, wherein the inflammatory disorder is sepsis.
- 74. (New) The method of claim 69, wherein the inflammatory disorder is reperfusion injury.
- 75. (New) The method of claim 69, wherein the inflammatory disorder is stroke.

Attorney Docket No. 08702.0090-04000  
Application No. 09/878,574

76. (New) The method of claim 69, wherein the inflammatory disorder is infection.